Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY041001 (HIIP), Human Insulin Inhalation Powder, Human Regular U-500 Insulin, Humulin R, U-500R, Huminsulin Regular, Huminsulin Normal, Humulin R U-500
LY041001 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| B | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| LY041001 (HIIP) | DRUG | Inhalation, capsule, TID 3 times per day min 6 IU max 60 IU |
Inclusion Criteria: * Type 2 diabetes for at least 12 months * Age 18 or older. * Taking at least 1 oral antihyperglycemic medication. * Have an HbA1C between 7.5 and 12. * Be a nonsmoker Exclusion Criteria: * Body Mass Index (BMI) greater than 40. * Have frequent episodes of severe hypoglycemia....
LY041001 is an investigational small molecule developed by Eli Lilly and Company for type 2 diabetes mellitus. It is also known as LY041001 (HIIP), a human insulin inhalation powder. It has been studied in a Phase 2 clinical trial and is not described as approved.
LY041001 was studied for the treatment of type 2 diabetes mellitus. The single Phase 2 trial evaluated intensive versus standard training for human insulin inhalation powder in adults with this condition. It is an investigational agent, and no approved use has been established for it.
LY041001 is developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the Phase 2 study of the human insulin inhalation powder in type 2 diabetes.
LY041001 is in Phase 2 development. One Phase 2 trial has been completed, and no active trials are listed. The study enrolled 97 participants and was randomized and controlled, though it was not double blind.
LY041001 has been studied in one Phase 2 trial, NCT00099515, titled Comparing Intensive and Standard Training for Human Insulin Inhalation Powder (HIIP). The completed trial enrolled 97 adults with type 2 diabetes across the United States, Argentina, Portugal, and South Africa, and it was randomized and controlled.
Yes, LY041001 is also known as LY041001 (HIIP), where HIIP stands for human insulin inhalation powder. The Phase 2 trial NCT00099515 used this HIIP designation in its title while studying adults with type 2 diabetes.